gp100: 280-288(288V) Peptide Vaccine

DRACPC ID  DRACPC0056

Active Ingredients   gp100: 280-288(288V) Peptide Vaccine

Description  A peptide vaccine consisting of the amino acids 280 through 288 of the melanoma antigen glycoprotein 100 (gp100) with potential antineoplastic activity. gp100:280-288(288V) peptide has a valine substitution at amino acid position 288 to improve immunogenicity. Vaccination with gp100:280-288(288V) peptide may stimulate the host immune system to mount a cytotoxic T lymphocyte (CTL) response against tumor cells positive for the gp100 antigen, resulting in decreased tumor growth.

Synonyms  Ovemotide; gp100: 280-288(288V) Peptide Vaccine

Type  Biotech

Disease  Melanoma

Classification

  

Peptide and derivative Vaccine 

Structure Information


Molecular Formula  C46H71N9O14

Molecular Weight  974.1

Active Sequence  YLEPGPVTV

Sequence Length  9

Modification  None

Structure

 

Show IUPAC/InChI/SMILES

IUPAC Name  (4S)-4-[[(2S)-2-[[(2S)-2-amino-3-(4-hydroxyphenyl)propanoyl]amino]-4-methylpentanoyl]amino]-5-[(2S)-2-[[2-[(2S)-2-[[(2S)-1-[[(2S,3R)-1-[[(1S)-1-carboxy-2-methylpropyl]amino]-3-hydroxy-1-oxobutan-2-yl]amino]-3-methyl-1-oxobutan-2-yl]carbamoyl]pyrrolidin-1-yl]-2-oxoethyl]carbamoyl]pyrrolidin-1-yl]-5-oxopentanoic acid

InChI  InChI=1S/C46H71N9O14/c1-23(2)20-31(50-39(61)29(47)21-27-12-14-28(57)15-13-27)40(62)49-30(16-17-35(59)60)45(67)55-19-9-10-32(55)41(63)48-22-34(58)54-18-8-11-33(54)42(64)51-36(24(3)4)43(65)53-38(26(7)56)44(66)52-37(25(5)6)46(68)69/h12-15,23-26,29-33,36-38,56-57H,8-11,16-22,47H2,1-7H3,(H,48,63)(H,49,62)(H,50,61)(H,51,64)(H,52,66)(H,53,65)(H,59,60)(H,68,69)/t26-,29+,30+,31+,32+,33+,36+,37+,38+/m1/s1

InChI_Key POVNCJSPYFCWJR-USZUGGBUSA-N

SMILES  O=C(O)CC[C@H](NC([C@@H](NC([C@@H](N)CC1=CC=C(O)C=C1)=O)CC(C)C)=O)C(N2[C@H](C(NCC(N3[C@H](C(N[C@@H](C(C)C)C(N[C@@H]([C@H](O)C)C(N[C@H](C(O)=O)C(C)C)=O)=O)=O)CCC3)=O)=O)CCC2)=O

External Codes


PubChem CID  9919490

DrugBank Accession Number  Not available

NCI Thesaurus Code  C49042  

UNII  Not available  

CAS  181477-91-8



Drug approval


Drug indication
    Investigated for use/treatment in melanoma.

    The drug is not approved.

ClinicalTrials.gov Identifier Title Condition or disease Phase Purpose
NCT00357461 A Randomized Phase II Study of Fixed Dose Ipilimumab (MDX-010) 10 mg/kg Given Alone or in Combination With Two gp100 Peptides Emulsified With Montanide ISA-51 VG for Previously Treated HLA-A * 0201 Positive Subjects With Stage IV Melanoma Melanoma (Skin) Phase 1 Treatment
NCT01176461 A Pilot Trial of a Vaccine Combining Multiple Class I Peptides and Montanide ISA 51 VG With Escalating Doses of Anti-PD-1 Antibody BMS-936558 for Patients With Unresectable Stages III/IV Melanoma Melanoma (Skin) Phase 1 Treatment
NCT01176474 A Phase I Trial of a Vaccine Combining Multiple Class I Peptides and Montanide ISA 51VG With Escalating Doses of Anti-PD-1 Antibody Nivolumab or Ipilimumab With Nivolumab For Patients With Resected Stages IIIC/ IV Melanoma Melanoma (Skin) Phase 1 Treatment

    More clinical information is obtained from ClinicalTrials.gov.





DRACP is developed by Dr.Zheng's team.